‘AVROBIO (AVRO) exploring potential sale after Novartis interest’ -Street Insider, Citing Sources
https://www.streetinsider.com/Hot+M+and+A/AVROBIO+%28AVRO%29+exploring+potential+sale+after+Novartis+interest+-+source/21181741.html
BTIG Upgrades Avrobio to Buy, Announces $4 Price Target
BTIG analyst Yun Zhong upgrades Avrobio (NASDAQ:AVRO) from Neutral to Buy and announces $4 price target.
AVROBIO Announces Clinical Data For Gaucher Disease Gene Therapy; Says ‘Following positive feedback from FDA and MHRA, registrational, global Phase 2/3 clinical trial for GD3 planned for second half 2023’
New compelling clinical data from first-ever Gaucher disease type 3 (GD3) patient and four Gaucher disease type 1 (GD1) patients dosed with investigational AVR-RD-02
Data from first pediatric GD3 patient, the more
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Nanobiotix (NASDAQ:NBTX) shares rose 16.4% to $2.7 during Friday's after-market session. The company's market cap stands at $94.1 million.
AVROBIO Announced Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy Annual Meeting; Said Data Support Plans to Initiate Clinical Trial in 2023
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease.
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
AVROBIO Inc (NASDAQ:AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a…
Needham Maintains Buy on Avrobio, Lowers Price Target to $6
Needham analyst Gil Blum maintains Avrobio (NASDAQ:AVRO) with a Buy and lowers the price target from $8 to $6.